Today: September 30, 2016, 3:32 pm

Argentina pharmaceutical market: Latest market analysis presented
The Pharmaceutical Market: Argentina - a new market research report on 2014-03-10 22:57:02
Argentina´s pharmaceutical market will become increasingly unattractive to multinational pharmaceutical companies, as the double-digit market growth has been mainly driven by the high inflation rate. The strict currency and import restrictions, as well as poor regulatory regime, have further undermined foreign drugmakers´ revenue-generating opportunities. A potential currency devaluation in the future will increase Argentina´s export of medicines to a certain extent, if the country´s structural distorting policies have not eroded its local pharmaceutical production capacity.

Headline Expenditure Projections

Pharmaceuticals: ARS31.30bn (US$7.58bn) in 2011 to ARS39.60bn (US$8.74bn) in 2012; +26.5% in local currency terms and 15.3% in US dollar terms. The forecast has increased since Q412 due to exchange rate fluctuations from previous years, and high inflation rate forecast for 2012.

Healthcare: ARS156.12bn (US$37.82bn) in 2011 to ARS198.71bn (US$30.23bn) in 2012; +27.3% in local currency terms and +16% in US dollar terms. The forecast has increased since Q412 due to over 25% inflation rate forecast for 2012.

Medical devices: ARS3.77bn (US$913mn) in 2011 to ARS4.39bn (US$971mn) in 2012; +16.5% in local currency terms and 6.2% in US dollar terms. The US dollar forecast has decreased since Q412 due to exchange rate fluctuations.

Risk/Reward Rating

Argentina remains at the eighth place in BMI´s RRRs in Q113. However, the poor regulatory regime and high inflation rate are still challenging for the multinational drug companies. The deteriorating business environment and protectionist policies will also have a negative impact on the market. Argentina´s pharmaceutical market is expected to grow at double-digit rates through to 2016 in local currency terms, largely due to inflation.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

Click for report details: ..

Browse all Healthcare and Medical Market Research Reports ..

Browse all Healthcare and Medical Company Profile Reports ..

Browse all Latest Market Research Reports ..

About Us is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles,’s online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.

Press Information

Published by
Mike King
London: +44 (0) 203 086 8600

# 505 Words
Related Articles
More From Finance
P2P lending platform Monexo partners with IDBI-Trusteeship [..]
For Immediate Release: 2nd September 2016 MUKESH BUBNA, CEO Monexo Fintech Pvt Limited P2P [..]
Day Trade to Win New September Class [..]
Sold Out? New Class Added – On September 6, 2016, is launching a brand new eight-week trading boot camp [..]
FTM (Forget The Market) Reopens 3 Shares [..]
Port Vila, Vanuatu, 28th July 2016 - Investment firm FTM today announced the reopening of three separate share options, projected [..]
Ex-Citibanker Launching Online P2P marketplace in India [..]
A study conducted by World Bank shows that MSMEs in India face an estimated credit gap of INR 20.9 trillion [..]
New Frontier Portfolios Top Morningstar Rankings
New Frontier’s global strategic portfolios topped the Global Balanced Strategic/All-Inclusive category of the latest Morningstar ETF [..]

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.